Updated findings from the clinical trial of the medication, which goes by the brand name Ukoniq, continued to show a possible increased risk of death. The agency determined the risks of the medication outweigh its benefits.
The FDA issued an accelerated approval of the drug Feb. 15, 2021. The manufacturer, TG Therapeutics, issued a voluntary recall of the drug April 15.
Healthcare providers should stop prescribing the medication to patients and seek alternative treatments, and patients should be informed of the risks and advised to cease taking the medication, according to the FDA.
“In limited circumstances in which a patient may be receiving benefit from Ukoniq, TG Therapeutics plans to make it available under expanded access,” the agency said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
